TRAF2- and NCK-interacting kinase (TNIK) (TNIK)

TRAF2- and NCK-interacting kinase (TNIK) is a serine/threonine kinase that has recently emerged as a high-priority novel target for the treatment of fibrotic diseases, most notably idiopathic pulmonary fibrosis (IPF). TNIK functions as a key transcriptional co-activator in the Wnt/beta-catenin signaling pathway, where it binds to TCF4 to drive the expression of genes essential for myofibroblast activation and extracellular matrix deposition [1]. The identification of TNIK's role in fibrosis was a landmark achievement for generative artificial intelligence in drug discovery, as the target was prioritized by AI platforms analyzing multi-omic data [2]. The lead therapeutic candidate targeting TNIK, Rentosertib (ISM001-055), is a small-molecule inhibitor that has demonstrated clinical efficacy in Phase IIa trials, showing significant improvements in forced vital capacity (FVC) compared to placebo [3]. Beyond pulmonary applications, TNIK inhibition is being explored for chronic kidney disease and liver fibrosis, given its central role in the fibrotic cascade across multiple tissues [4]. Safety profiles for TNIK inhibitors have generally been favorable, though potential concerns remain regarding the systemic inhibition of Wnt signaling, which is vital for normal tissue homeostasis, particularly in the gastrointestinal tract [5]. Note: The provided target name 'Unknown novel fibrosis-related target' is a generic description; the information here describes TNIK, the most prominent novel fibrosis target identified by AI.

Other names

Germinal center kinase-like kinaseGCK-like kinaseTraf2- and Nck-interacting kinaseTNIK

Inhibition of TNIK kinase activity, which prevents the formation of the TNIK-TCF4 transcriptional complex and suppresses the Wnt/beta-catenin-mediated expression of pro-fibrotic genes and myofibroblast activation.